Core Viewpoint - Minsheng Securities received a warning letter from the Zhejiang Securities Regulatory Bureau due to inadequate supervision of the listed company, Weikang Pharmaceutical, during its initial public offering process [2][3]. Group 1: Violations by Minsheng Securities - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and did not conduct sufficient verification procedures [2]. - The internal controls of Minsheng Securities' investment banking business were found to be deficient, leading to insufficiently cautious conclusions in the continuous supervision documents for Weikang Pharmaceutical's 2023 fiscal year [2][6]. Group 2: Consequences for Weikang Pharmaceutical - Weikang Pharmaceutical was previously fined 14 million due to violations related to information disclosure, with a total penalty of 14.6 million imposed on the company and its responsible individuals [4]. - Specific penalties included a 5 million fine for Weikang Pharmaceutical, 7 million for its actual controller Liu Zhongliang, and additional fines for other responsible personnel [4]. Group 3: Regulatory Context - The actions of Minsheng Securities violated the "Administrative Measures for Sponsoring Securities Issuance and Listing" [3]. - The regulatory environment has increasingly emphasized accountability, with multiple securities firms facing penalties for issues related to sponsored companies, indicating a shift from a focus on underwriting to comprehensive accountability in the investment banking sector [6].

Core Viewpoint - The article highlights the regulatory scrutiny on continuous supervision responsibilities of securities firms, specifically focusing on Minsheng Securities' failures in overseeing Weikang Pharmaceutical's IPO process [2][4]. Group 1: Violations in Continuous Supervision - Minsheng Securities, as the continuous supervision institution for Weikang Pharmaceutical's IPO, failed to adequately address significant issues such as construction project delays and insufficient verification procedures [4]. - The internal controls of the investment banking business at Minsheng Securities were found lacking, leading to cautious conclusions in the supervision documents for Weikang Pharmaceutical [4]. Group 2: Weikang Pharmaceutical's Performance Issues - Weikang Pharmaceutical, which went public in August 2020, has faced a continuous decline in net profit since its listing, with a reported loss of 8.039 million yuan in 2023, a year-on-year decrease of 116.47% [5]. - The company's performance worsened in 2024, with an estimated annual loss of 147 million yuan, and in the first half of 2025, revenue dropped by 61.42% and net profit fell by 552.50% [5]. Group 3: Regulatory Actions and Consequences - Weikang Pharmaceutical has faced multiple regulatory penalties due to issues such as information disclosure violations and improper fund usage, with fines exceeding 14 million yuan imposed on the company and its actual controller [5][6]. - The investigation revealed that from 2020 to June 2023, the actual controller misappropriated over 150 million yuan from the company, which was not disclosed in regular reports [6]. Group 4: Broader Industry Implications - The regulatory environment for continuous supervision in the investment banking sector has tightened, with several securities firms facing penalties for inadequate diligence in their supervisory roles [8]. - The introduction of a new classification system for underwriters, including a "suspended business" category, reflects the increasing regulatory pressure and the need for stricter compliance within the industry [8].

【导读】维康药业IPO持续督导失责，民生证券及两名保代被警示 监管对券商持续督导责任的要求正持续强化。 10月21日，浙江证监局披露，经查，民生证券（现为国联民生证券）作为浙江维康药业股份有限公司（以下简称维康药业）首次 公开发行股票持续督导机构，在持续督导履职过程中存在违规行为，任绍忠、钟德颂作为保荐代表人对上述违规行为负有主要责 任。 持续督导存在两大违规问题 保荐项目上市后"业绩变脸" 一是未充分关注在建工程延期异常情况，核查程序不充分。二是在出具维康药业2023年度持续督导文件过程中，核查结论不够谨 慎，投行业务内部控制存在缺陷。任绍忠、钟德颂作为保荐代表人，对上述违规行为负有主要责任。 据悉，国联民生证券的投行业务正处于整合过渡期。9月23日，国联民生公告称，收购后，国联民生承销保荐与民生证券投资银 行业务整合，国联民生承销保荐被确定为投资银行业务整合后的业务开展主体。自9月23日起，民生证券所有项目（含持续督导 项目清单中的项目）将并入国联民生承销保荐。 维康药业于2020年8月登陆创业板，主营业务为现代中药及西药的研发、生产和销售。然而，公司上市后旋即出现"业绩变脸"， 净利润自上市次年起连续下 ...

Group 1 - The Zhejiang Securities Regulatory Bureau announced that Minsheng Securities, as the continuous supervision institution for Weikang Pharmaceutical Co., Ltd., violated regulations during its supervisory duties, particularly regarding the insufficient attention to the abnormal delays in construction projects and inadequate verification procedures [1] - The regulatory body highlighted that the conclusions drawn during the issuance of Weikang Pharmaceutical's 2023 annual continuous supervision documents were not cautious enough, indicating flaws in the internal controls of the investment banking business [1] - As a result of these violations, the Zhejiang Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure against Minsheng Securities and the responsible representatives Ren Shaozhong and Zhong Desong [1]

Core Points - Zhejiang Securities Regulatory Bureau issued a decision regarding Minsheng Securities for violations during the continuous supervision of Weikang Pharmaceutical's IPO [1] - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and lacked sufficient verification procedures [1] - The internal controls of the investment banking business were found to be deficient, leading to insufficiently cautious conclusions in the continuous supervision documents for Weikang Pharmaceutical for the year 2023 [1] - The actions of Minsheng Securities violated the Securities Issuance and Listing Sponsorship Business Management Measures [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, were held primarily accountable for the violations [1] - As a result, the Zhejiang Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure [1]

Core Viewpoint - The Zhejiang Securities Regulatory Bureau has issued a decision regarding Minsheng Securities Co., Ltd. for violations during its continuous supervision of Zhejiang Weikang Pharmaceutical Co., Ltd.'s initial public offering process [1] Group 1: Violations Identified - Minsheng Securities failed to adequately monitor the abnormal delays in construction projects and did not perform sufficient verification procedures [1] - The conclusions drawn in the continuous supervision documents for Weikang Pharmaceutical in 2023 were not cautious enough, indicating deficiencies in internal controls within the investment banking operations [1] Group 2: Regulatory Actions - The actions of Minsheng Securities violated Article 5, Paragraph 1 of the "Administrative Measures for Sponsorship of Securities Issuance and Listing" (CSRC Order No. 170) [1] - The responsible representatives, Ren Shaozhong and Zhong Desong, are held primarily accountable for the violations [1] - The Zhejiang Securities Regulatory Bureau has decided to issue a warning letter as an administrative regulatory measure against Minsheng Securities [1]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Investment Rating - The industry maintains an "Overweight" rating [8] Core Insights - The Chinese medicine sector outperformed other pharmaceutical sub-sectors last week, with a 0.38% increase, while the overall pharmaceutical sector declined by 2.48% [2] - The current PE (ttm) for the Chinese medicine sector is 27.9X, which is at the 30.45% percentile since 2013, while the PB (lf) is 2.36X, at the 6.85% percentile since 2013 [3] - The price index for Chinese medicinal materials remained stable due to the National Day holiday, with a total index of 232.77 points [4] - A pilot program for disease-based payment for traditional Chinese medicine (TCM) is set to begin, which may enhance reimbursement for TCM services [5] Summary by Sections Market Performance - The Chinese medicine sector recorded a 0.38% increase, while the overall pharmaceutical sector saw a decline of 2.48% [2] - Top-performing companies in the sector include Guizhou BaiLing, Wanbangde, and Darentang, while underperformers include Tianmu Pharmaceutical and Tailong Pharmaceutical [2] Valuation - The PE (ttm) for the Chinese medicine sector is 27.9X, up 0.1X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [3] - The PB (lf) is 2.36X, unchanged from the previous week, with a one-year maximum of 2.59X and a minimum of 2.17X [3] Policy Developments - The pilot program for TCM payment will select around 15 provinces or cities to test the new payment model over 2-3 years, potentially improving the compatibility of TCM services with existing insurance payment methods [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][11][12] - Specific recommendations include companies with strong R&D capabilities and unique products, as well as those less affected by price reductions from centralized procurement [12]

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Core Viewpoint - The innovative drug concept stocks continue to be active, with significant gains observed in several companies [2] Company Performance - Huabang Health reached the daily limit increase in stock price [2] - Other companies such as Shenlian Bio, Shutaishen, Chenxin Pharmaceutical, Weikang Pharmaceutical, and Hite Bio also experienced upward movement in their stock prices [2]